RxDoctor Payments Data

Paul Barbera, MD

Internal Medicine · Sparrows Point, MDNPI 1053459487

Payments from drug & device makers

$1,387in general payments, 2019–2025

Across 70 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$301
  • Novo Nordisk$241
  • Pfizer$179
  • Astellas Pharma US Inc$127
  • Boehringer Ingelheim$98
  • GSK$92
  • plus $350 from 9 others

What the payments were for

  • Food & beverage$1,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,387 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$119,793
Medicare patients
184
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$80,510
EliquisApixaban73$70,985
OzempicSemaglutide49$52,171
TrulicityDulaglutide20$41,759
JardianceEmpagliflozin30$36,240
LinzessLinaclotide33$30,174
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$28,267
SuboxoneBuprenorphine Hcl/Naloxone Hcl53$27,792
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$26,711
MounjaroTirzepatide23$23,241
RybelsusSemaglutide15$23,223
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$18,729
JanuviaSitagliptin Phosphate11$15,474
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$13,587
Breo ElliptaFluticasone/Vilanterol14$13,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$92$107,462118 claims
PfizerEliquis, Prempro, Premarin$179$76,47299 claims
Novo NordiskOzempic, Rybelsus$241$75,39464 claims
Lilly USA, LLCTrulicity, Mounjaro$91$64,99943 claims
Boehringer IngelheimJardiance$98$36,24030 claims
AbbVieLinzess$24$30,17433 claims
Indivior Inc.Suboxone$70$27,79253 claims
AstraZenecaBreztri Aerosphere$301$26,71130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Sparrows Point

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →